Industry pipeline for mAbs reaches an unprecedented scale
Steep rise in type 2 diabetes in South-East Asia
Successor to PD-1 inhibitors the focus of cancer immunotherapy
Asia-Pacific hepatitis C market to surpass $8.3 billion by 2023
Roche will remain oncology market leader to 2023, says GBI Research
Painkillers market to hit $28.8 billion by 2023 thanks to new drug approvals
Asia-Pacific asthma market predicted to hit $6bn by 2023
Haematological cancers pipeline one of the strongest in oncology
Integrated lifecycle management strategies are vital, says GBI
APAC non-small cell lung cancer market to double
Key biologics patents expiring in 2020
Head and neck cancer market offers fertile ground for investors
Biogen to remain leader in neurodegenerative drugs
Low medication compliance rate in lupus patients
Immunology attracting high level of investment
